Jubilant Pharmova Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Jubilant Pharmova Ltd · Outcome · 14 Nov 2026, 1:38 am
Jubilant Pharmova Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 23,700 (+20.5% YoY | +6.3% QoQ) ■ EBITDA: 2,405 (-29.6% YoY | -3.0% QoQ) ■ EBITDA Margin (%): 10.1 (-721 bps YoY | -98 bps QoQ) ■ PAT: 312 (-74.1% YoY | -44.8% QoQ) ■ EPS (INR): 1.96 (-74.1% YoY | -44.9% QoQ) Jubilant Pharmova Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Radiopharma ■ Revenue: 10,093 (+12.5% YoY | -1.3% QoQ) ■ EBIT: 698 (-26.9% YoY | -10.5% QoQ) ■ EBIT Margin (%): 6.9 (-373 bps YoY | -72 bps QoQ) Allergy Immunotherapy ■ Revenue: 2,295 (+18.3% YoY | +7.0% QoQ) ■ EBIT: 657 (-12.3% YoY | +3.5% QoQ) ■ EBIT Margin (%): 28.6 (-998 bps YoY | -99 bps QoQ) Contract Development and Manufacturing Organisation - Sterile Injectables ■ Revenue: 5,596 (+36.0% YoY | +7.7% QoQ) ■ EBIT: -42.0 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -0.8 (Profit to Loss YoY | Profit to Loss QoQ) Contract Research, Development and Manufacturing Organisation ■ Revenue: 3,448 (+10.3% YoY | +5.8% QoQ) ■ EBIT: 200 (-31.0% YoY | -43.8% QoQ) ■ EBIT Margin (%): 5.8 (-348 bps YoY | -513 bps QoQ) Generics ■ Revenue: 2,741 (+64.1% YoY | +58.1% QoQ) ■ EBIT: 51.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 1.9 (Loss to Profit YoY | Loss to Profit QoQ) Proprietary Novel Drugs ■ Revenue: 0.0 ■ EBIT: -102 (-251.7% YoY | -34.2% QoQ) ■ EBIT Margin (%): 0.0
Original exchange filing (PDF)
More announcements from Jubilant Pharmova Ltd
- Investor Meet Outcome · 16 Nov 2026
- Press Release · 14 Nov 2026
- Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Press Release · 11 Nov 2026
- Allotment · 06 Nov 2026
- Allotment of NCD · 06 Nov 2026
- Earning Webinar · 16 Nov 2026
